Skip to content

Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease

Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease in Populations of High vs. Low Tuberculosis Endemicity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01503099
Enrollment
550
Registered
2012-01-02
Start date
2009-10-31
Completion date
2012-12-31
Last updated
2012-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease, Intestinal Tuberculosis, Pulmonary Tuberculosis

Keywords

ITB, PTB, CD

Brief summary

One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.

Detailed description

Intestinal tuberculosis (ITB) and Crohn's disease (CD) may present identically; the consequence of misdiagnosing and mistreating one disease for the other may be grave. CD is on the increase worldwide while TB re-emerges in areas of low TB endemicity. Current diagnostic guidelines evolve from research in areas with low TB prevalence, thereby being inappropriate in TB endemic regions. To date, no simple or non-invasive methods exist to diagnose ITB and to differentiate it from CD. One aims to devise a method for screening and differentiation of the two diseases. By using non-invasive rapid tests one wishes to make diagnostics available to resource poor settings. Ideally, referrals to invasive diagnostic procedures would decrease, thus liberating economic and staff resources. Furthermore, patients may avoid unnecessary, expensive and often inconclusive advanced procedures. Additionally, one aims to detect and survey multidrug resistance caused by empiric TB treatment, which in itself obscures ITB diagnosis. This case control study matches 50 ITB patients and 50 CD patients with 100 healthy controls in India, and 50 CD patients with 100 healthy controls in Norway. Comparative statistical analysis will be carried out. Challenges include patient adherence and sample handling. Non-TB gastrointestinal infections may confound the results and will be adjusted for. Recently published data suggests that the serum/faecal calprotectin ratio may be used to discriminate ITB from healthy subjects.

Interventions

None listed

Sponsors

Helse Sor-Ost
CollaboratorOTHER_GOV
The Unger-Vetlesen Medical Fund, Jersey, C.I
CollaboratorUNKNOWN
Odd Fellow Medical Fund, Norway
CollaboratorUNKNOWN
Lovisenberg Diakonale Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Above 18 years of age. * ITB as per standard criteria a), and one or more of b) to e) must be fulfilled (Gold standard): 1. Endoscopic apparent intestinal tuberculosis: transverse ulcers, pseudopolyps, involvement of fewer than four intestinal segments, patulous ileo-coecal valve 2. Histological evidence of tubercles/granulomas with caseation necrosis in intestinal biopsies 3. DNA of M.tb detected by PCR of intestinal biopsies 4. Positive immunohistochemistry in intestinal biopsies. 5. Histological demonstration of acid fast bacilli in a lesion. * Active Crohn's disease as per standard criteria (Gold standard), at least two of the following: 1. Clinical: inflammatory, perforating (fistulising) disease, obstructive symptoms secondary to small bowel stenosis or stricture. 2. Endoscopic: deep linear or serpingenous ulcerations, discrete ulcers in normal appearing mucosa, cobble-stoning or discontinuous or asymmetrical inflammation. 3. Radiographic: segmental disease (skip lesions), small bowel or colonic strictures, stenosis or fistula. 4. Histological: sub-mucosal or transmural inflammation, granulomas, focal cryptitis and chronic inflammatory infiltration, skip lesions including rectal sparing (no topical rectal therapy).

Exclusion criteria

a) Age below 18 years b) HIV positive c) Malignancy

Design outcomes

Primary

MeasureTime frameDescription
Calprotectin levels in patients with active intestinal tuberculosis18 monthsEstablishment of serum and faecal calprotectin levels in patients with active intestinal tuberculosis in comparison with healthy control subjects, patients with Crohn's Disease and patients with active pulmonary tuberculosis.

Secondary

MeasureTime frame
Levels of calprotectin in patients with intestinal tuberculosis after antituberculous therapy.18 months

Countries

India, Norway

Contacts

Primary ContactGeir larsson, M.D
geirlarsson@yahoo.com+47 92045245

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026